StudyFinder
Rituximab-PVVR followed by Abatacept Versus Rituximab-PVVR Alone In New Onset Type 1 Diabetes
Recruiting
This study is to see if giving the medications rituximab-pvvr (Ruxience®) followed by abatacept can help preserve remaining insulin secretion if given within three months of being diagnosed with type 1 diabetes (T1D).
Male or Female
Not specified
Inclusion Criteria:
• 8 to 45 years old
• diagnosis of Type 1 Diabetes within 100 days of starting the study
• positive for at least one islet cell autoantibody
• willing to comply with intensive diabetes management
• willing to wear a continuous glucose monitoring device for a minimum of 10 days every 6 months
• weigh at least 20kg (44 pounds)
• up to date on all recommended vaccinations based on age
• willing to practice public health prevention measures such as social distancing, masking, and good hand hygiene, and/or receive therapeutics such as monoclonal antibodies and antivirals as directed by the study and recommended by local health authorities to prevent SARS-Cov-2 infection
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:
• history of immune deficiency
• chronic active infection other than localized skin infections
• current or past HIV or Hepatitis B or active Hepatitis C infection
• women who are pregnant, breast feeding, or anticipate pregnancy
• use of oral or inhaled steroids or other immunosuppressive agents
• history of cancer
Diabetes & Endocrine
DM, T1D, Type 1 Diabetes
Veronica Jones-Carr - jone2678@umn.edu
Antoinette Moran
STUDY00021237